Claim OwnershipPETRI DISH PERSPECTIVES
Subscribed: 0Played: 9
Subscribe
© 2026 PETRI DISH PERSPECTIVES
Description
Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎
Stream new episodes every THURSDAY!
https://linktr.ee/maneadkhin
#biotech #pharma #healthcare #podcast #petridishperspectives
55 Episodes
Reverse
Send us Fan Mail In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But the road to this exit wasn't paved with easy wins, it was forged in the wreckage of a "zombie" penny stock that almost didn't survive 2008. We take you through the high-stakes gamble of the DeeP-C trial, the behavioral economics behind ...
Send us Fan Mail In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology. We break down the leaders of this revolution, comparing the "TechBio" pioneers like Insilico and Recursion with the massi...
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026! This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the company positioned itself not as a traditional biotech, but as a “organism engineering foundry.” We break down Ginkgo’s unique business model, partnering with companies across pharma, agriculture, and consumer goods and how it generates value throug...
Send us Fan Mail From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech. In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how Dilip Shanghvi transformed a niche generics business into one of the largest pharmaceutical companies in the world. We explore Sun Pharma’s early focus on underserved therapeutic areas, its aggressive strategy of acquirin...
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the physician-pharmacist Jacques Servier, the company grew from a tiny laboratory in Orléans into a global powerhouse in cardiovascular and metabolic medicine. For decades, Servier built its reputation developing treatments for hypertension and dia...
Send us Fan Mail Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world. In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how BioMarin became one of the most influential rare-disease biotech companies in the industry. We explore the company’s founding vision, the scientific pathways behind its major ther...
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026! This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything. In this episode of Petri Dish Perspectives: Biotech Unleashed, we explore how BioNTech evolved from an academic vision into one of the most important biotechnology companies of the 21st century. We break down the scientific bet on mRNA, the early years building a...
Send us Fan Mail In this episode of Petri Dish Perspectives, we unpack the strategy and scientific conviction behind ARCH Venture Partners, the venture firm that has quietly helped build some of the most transformative companies in modern biotechnology. From early bets on platform technologies like gene editing and mRNA to backing next-generation leaders such as Juno, Editas Medicine, Beam Therapeutics, and rising metabolic players like Metsera, ARCH has consistently invested at the frontier,...
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the fascinating evolution of Otsuka Holdings, a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused business to becoming a global biopharma innovator, Otsuka has built its reputation by targeting complex and often misunderstood disease areas such as psychiatric disorders, kidney disease, and digital medicine. We unpack the scientific and business journe...
Send us Fan Mail What if medicine could fix disease at its source… by rewriting the genetic code itself? In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut the field down, and finally to today’s life-changing treatments for rare diseases, cancer, and gen...
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026! This month was dominated by a surge in Eli Lilly's deals, partnerships, etc. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away? In this episode, we explore the remarkable story of Eisai, the Japanese pharmaceutical company that built its global identity around Alzheimer’s disease. From its founding during World War II and early commitment to ethical medicine, to the blockbuster success of Aricept, and finally the long, controversial road to Leqembi, Eisai’s journey is one of persist...
Send us Fan Mail Flagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his early life shaped by uncertainty to the founding of a firm that treats biology like an engineering discipline, we explore how Flagship redefined what it means to create companies from first principles. We unpack how Flagship pioneered t...
Send us Fan Mail Biogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial field long before most pharma companies dared to enter it. In this episode, we trace Biogen’s full journey, from its academic origins and the rise of interferon therapies for multiple sclerosis, to blockbuster drugs like Avonex and Tysa...
Send us Fan Mail Theranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history. In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its founding in 2003 to its dramatic collapse and criminal convictions nearly two decades later. We explore how ambition, secrecy, and Silicon Valley mythology allowed unproven science to scale into a $9 billion company, how powerful board members...
Send us Fan Mail Novo Nordisk’s rise is one of the most extraordinary stories in modern medicine. What began in 1920s Denmark as a response to a fatal disease evolved into a company that reshaped how the world treats diabetes, obesity, and metabolic illness. In this episode, we trace Novo Nordisk’s journey from the discovery of insulin and a decades-long rivalry between two Danish labs, to a landmark merger, global expansion, and steady leadership in diabetes care. We explore how the company ...
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for December 2025! This month was dominated by a surge in M&A activity and licensing deals. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail Before there were blockbuster drugs, clinical trials, and biotech startups, there was… dye. In this episode of Petri Dish Perspectives, we explore one of the most overlooked origin stories in modern medicine: how 19th-century chemical dye companies laid the foundation for today’s pharmaceutical giants. From coal tar chemistry and synthetic pigments to the birth of industrial drug discovery, this episode unpacks why companies like Bayer, BASF, Ciba, and Hoechst evolved from co...
Comments
Download from Google Play
Download from App Store
United States